Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy

Santiago Mercadal; Kwang Woo Ahn; Mariam Allbee-Johnson; Siddhartha Ganguly; Praveen Ramakrishnan Geethakumari; Sanghee Hong; Adriana Malone; Hemant Murthy; Attaphol Pawarode; Alejandro R Sica; Melhem Solh; Celalettin Ustun; Mazyar Shadman; Craig S Sauter; Mehdi Hamadani; Alex F Herrera; Catherine J Lee

doi:10.3324/haematol.2024.285613

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy

Haematologica. 2025 Jan 1;110(1):218-221. doi: 10.3324/haematol.2024.285613.

Authors

Santiago Mercadal¹, Kwang Woo Ahn², Mariam Allbee-Johnson², Siddhartha Ganguly³, Praveen Ramakrishnan Geethakumari⁴, Sanghee Hong⁵, Adriana Malone⁶, Hemant Murthy⁷, Attaphol Pawarode⁸, Alejandro R Sica⁹, Melhem Solh¹⁰, Celalettin Ustun¹¹, Mazyar Shadman¹², Craig S Sauter¹³, Mehdi Hamadani¹⁴, Alex F Herrera¹⁵, Catherine J Lee¹²

Affiliations

¹ Utah Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
² Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
³ Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY; Section of Hematology, Houston Methodist Hospital and Neal Cancer Center, Houston, TX.
⁴ Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.
⁵ Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC.
⁶ Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.
⁷ Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL.
⁸ Division of Hematology/Oncology, Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan Medical School, Ann Arbor, MI.
⁹ Department of Hematology-Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.
¹⁰ Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
¹¹ Rush University Medical Center, Chicago, IL.
¹² Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
¹³ Hematology/Medical Oncology, Cleveland Clinic, Cleveland, OH.
¹⁴ BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI. mhamadani@mcw.edu.
¹⁵ City of Hope, Duarte, CA.

No abstract available

Grants and funding

Funding: The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); HHSH250201700006C from the Health Resources and Services Administration (HRSA); and N00014-20-1-2705 and N00014-20-1-2832 from the Office of Naval Research; Support is also provided by Be the Match Foundation, the Medical College of Wisconsin, the National Marrow Donor Program, and from the following commercial entities: Actinium Pharmaceuticals Inc.; Adienne SA; Allovir Inc.; Amgen Inc.; Angiocrine Bioscience; Astellas Pharma US; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co. Ltd.; ExcellThera; Fate Therapeutics; Gamida-Cell Ltd.; Genentech Inc; Incyte Corporation; Janssen/Johnson & Johnson; Jazz Pharmaceuticals Inc.; Kiadis Pharma; Kite, a Gilead Company; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Merck Sharp & Dohme Corp.; Millennium, the Takeda Oncology Co.; Miltenyi Biotec Inc.; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune Inc.; Orca Biosystems Inc.; Pfizer Inc.; Pharmacyclics, LLC; Sanofi Genzyme; Stemcyte; Takeda Pharma; Vor Biopharma; Xenikos BV.